Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Role of immune cells in the removal of deleterious senescent cells

Abhijit Kale, Amit Sharma, Alexandra Stolzing and 2 more

Immunity & Ageing · 2020 · Review · CC BY

doi:10.1186/s12979-020-00187-9

Abstract

Cellular senescence is an essentially irreversible arrest of cell proliferation coupled to a complex senescence-associated secretory phenotype (SASP). The senescence arrest prevents the development of cancer, and the SASP can promote tissue repair. Recent data suggest that the prolonged presence of senescent cells, and especially the SASP, could be deleterious, and their beneficial effects early in life can become maladaptive such that they drive aging phenotypes and pathologies late in life. It is therefore important to develop strategies to eliminate senescent cells. There are currently under development or approved several immune cell-based therapies for cancer, which could be redesigned to target senescent cells. This review focuses on this possible use of immune cells and discusses how current cell-based therapies could be used for senescent cell removal.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

Cellular senescence entails an essentially irreversible arrest of proliferation in damaged or stressed cells that are at risk of malignant transformation. Two main pathways establish and maintain this growth arrest, which is a potent anti-cancer mechanism. One pathway is governed by p53 (a tumor suppressor and transcriptional regulator) and p21 (a cyclin-dependent kinase (CDK) and cell cycle inhibitor). The other pathway is governed by p16INK4a (a tumor suppressor and CDK/cell cycle inhibitor) and pRB (a tumor suppressor and transcriptional regulator). Several stimuli can trigger these pathways, leading to senescence in cultured cells and in vivo. Important stimuli for senescence include replicative exhaustion, which generally results in telomere attrition (also known as replicative senescence), and DNA-damage such as that caused by ionizing and, to some extent, non-ionizing radiation. In addition, some chemotherapeutic drugs such as doxorubicin or bleomycin also cause DNA damage, and other drugs such as abemaciclib or palbociclib inhibit CDKs directly to induce a senescence arrest. Consistent with senescence being an antitumor mechanism, the activation of certain oncogenes such as RAS or BRAF leads to oncogene-induced senescence (OIS). Further, events that disrupt mitochondrial function triggers a mitochondrial dysfunction-associated senescence (MiDAS) arrest, and oxidative stress and inhibitors of DNA methylases or histone deacetylases also cause a senescence arrest (Fig. 1).

The senescence arrest is generally coupled to a complex senescence-associated secretory phenotype (SASP). The SASP is conserved between mice and humans, and even to some extent between mammals and insects. Its components include growth factors, chemokines and cytokines, proteases, bioactive lipids and extracellular vesicles, many of which are pro-inflammatory. The number of senescent cells increases with age in most tissues, although they rarely exceed a few percent. Nonetheless, mounting evidence suggests that senescent cells can drive a surprisingly diverse array of aging phenotypes and diseases, mainly through the SASP. The presence of senescent cells also exacerbates several diseases including, but not limited to, osteoarthritis, osteoporosis, atherosclerosis, Parkinson’s disease, and Alzheimer’s disease. Importantly, eliminating senescent cells in transgenic mouse models often delays age-related tissue dysfunction and increases health span. Furthermore, several laboratories are developing new classes of drugs termed senolytics, which kill senescent cells, or senomorphics, which alleviate SASP effects. These drugs can help maintain homeostasis in aged or damaged tissues, and postpone or ameliorate many age-related pathologies.

In contrast to their deleterious roles in driving aging and age-associated diseases, senescent cells can have beneficial roles during development and tissue repair, regeneration and reprogramming. For example, in mice, the SASP from senescent cells enhances reprogramming in neighboring cells, and the short-term expression of reprogramming factors promotes tissue regeneration and reduces tissue aging. Senescent cells can also promote wound healing in the skin and liver, and either promote or suppress fibrotic responses depending on the tissue and biological context. Senescent cells also optimize mouse embryogenesis, and the absence of senescent cells can delay development and promote patterning defects. In adult animals, senescent cells promote heart regeneration, and their elimination can impair regeneration and repair in this tissue.

Current thinking is that the short-term presence of senescent cells is beneficial, largely by adjusting the plasticity of neighboring cells, but that their prolonged presence can be deleterious. This apparent dichotomy of the impact of cellular senescence on health and disease suggests that cellular senescence is an example of antagonistic pleiotropy, the evolutionary theory that predicts there are traits that have been selected for their beneficial effects early in life, but late in life these traits can be maladaptive and drive phenotypes and pathologies associated with aging.

The timely clearance of senescent cells is required to maintain tissue and organismal homeostasis. Although cellular senescence has been studied in detail in the context of disease, the interaction of senescent cells with immune cells have been less thoroughly investigated. Due in large measure to the SASP, senescent cells likely interact extensively with the immune system. The production and secretion of SASP factors (resulting in local inflammation) can be a potent means to recruit immune cells. The SASP recruits macrophages, natural killer (NK) cells, neutrophils and T lymphocytes, which eliminate them, but senescent cells can also interact with immune cells to avoid elimination.

The immune system was first shown to eliminate senescent cells in a study demonstrating that reactivation of p53 in hepatic tumors causes the tumor cells to senesce, followed by ‘selective’ recruitment of macrophages, neutrophils and NK cells by the SASP-producing senescent cells. Subsequently, p53 was shown to promote the secretion of chemokines like CCL2 to attract NK cells for the clearance of senescent cancer cells. A role for the SASP in immune clearance of senescent cells was further highlighted by the finding that the epigenetic regulator BRD4, which dictates the enhancer and super-enhancer landscape of SASP genes, determines the ability of the SASP to promote immune clearance of senescent cells. Thus, BRD4 inhibition significantly reduces the SASP, which severely limits the ability of the immune system to eliminate senescent cells. Further, expression of the scavenger receptor CD36 is sufficient to induce a SASP in normal dividing cells, suggesting an important role for this receptor in SASP signaling. Here, we first describe the function of various cell types of the immune system, and then discuss possible therapies for the elimination of senescent cells by immune cells.

Interaction of senescent cells with macrophages

Monocytes-macrophages belong to a class of multifunctional innate immune cells prevalent throughout the body, and maintain tissue homeostasis and repair by regulating various biological processes such as angiogenesis and tissue remodeling. These innate immune cells recognize and eliminate bacterial pathogens based on pathogen-specific molecular patterns. Thus, macrophages are important players in resolving infections. They also can promote certain diseases such as asthma, rheumatoid arthritis, cancer and atherosclerosis.

These antigen-presenting cells are classically divided into two phenotypically distinct subgroups (M1 and M2), but with a high degree of plasticity somewhat similar to the Th1 and Th2 classification assigned to T cells. Exposure to intracellular pathogens and their components, such as lipopolysaccharide (LPS) or cytokines such as interferon (IFN)-γ, can trigger an M1-type phenotype in macrophages, which produce ‘pro-inflammatory’ molecules. These molecules include interleukins (IL)-1β, IL-6, IL-8, IL-12 and IL-15, tumor necrosis factor (TNF)-α and chemokines to enhance the clearance of pathogens. M1-like cells also show increased major histocompatibility complex (MHC) class II expression, and increased inducible nitric oxide synthase activity.

M2-type macrophages are phenotypically distinct macrophages that respond to type II cytokines such as IL-4 and IL-13, in addition to counteracting the effects of IL-1β signaling. These cytokines upregulate arginase-1, which shifts metabolism to reduce nitric oxide production but increase polyamine and proline production, which stimulate cell growth, dynamic changes in collagen and tissue repair. M2-type macrophages also produce high levels of IL-10 and matrix metalloproteinase (MMP)-12, as well as chemo-attractants such as CCL-8 and CCL-13 to attract eosinophils and basophils to resolve tissue damage.

One primary function of macrophages is resolution of inflammation by ‘clearing’ culprit damaged cells. The role of macrophages in eliminating senescent cells was first demonstrated a decade ago. In mice, macrophages clear senescent cells in the uterine stroma surrounding the embryo implantation site following parturition. In addition, senescent hepatic stellate cells secrete a SASP that not only attracts macrophages, but also converts cytotoxic M1 cells to the M2 state. Stellate cells undergoing senescence preferentially secrete IL-6, ICAM1 and IFN-γ, triggering M1 polarization, whereas proliferating stellate cells secrete IL-3, IL-4, and IL-5, among other factors, which shift macrophages to the M2 state. Aging diminished the ability of macrophages to respond to a cytokine that shifted resident macrophages to an M1 state but caused paradoxical IL-4-driven polarization of resident macrophages toward the M1 state. The expression of p16INK4a in macrophages can suppress M1 polarization and hence the secretion of inflammatory factors by these cells. On the other hand, the SASP secreted by senescent thyroid cells skews macrophage polarization to M2 caused by prostaglandin E2, a prominent SASP factor.

There are several unanswered questions regarding the interplay between senescent cells and macrophages and how this interplay influences age-related inflammation or what is now termed inflammaging. Recent findings in murine models show that some cells with elevated p16INK4a and senescence-associated beta-galactosidase (SA-β-Gal) expression (common biomarkers of senescence) are likely macrophages, and that these macrophages exhibit other phenotypes associated with cellular senescence. These senescent-like macrophages increase with age, and might exacerbate the rise in senescent cells and the SASP during aging by a paracrine effect, which was recently shown to occur in vivo. Furthermore, eliminating this subset of so-called senescent-like or pseudo senescent macrophages with an M2 phenotype induces a striking resolution of inflammation. Recent work also shows that the SASP can promote macrophage proliferation and increased expression of CD38, which enhances the consumption of NAD by macrophages and might explain the age-related decline in NAD levels.

M1 and M2 macrophages are still difficult to distinguish. There is a consensus that macrophages can switch their phenotypes to those associated with M1 and M2 states in response to different microenvironments. Indeed, M1 and M2 macrophages vary in phagocytic activity in response to their microenvironment. Thus, macrophages and senescent cells may interact depending on the specific SASP signature and ligands present on senescent cells, which in turn depends on the lineage of cells undergoing senescence and the nature of the insult responsible for inducing senescence (Fig. 1).

Interaction of natural killer cells with senescent cells

NK cells were originally described as ‘Large Granular Lymphocytes’ with natural innate ability to kill cancer cells. Since then, these innate immune cells were shown to eliminate aberrant cells, including virally infected cells, ‘stressed’ cells and cancer cells without prior stimulation or activation. NK cells appear to function primarily by surveilling MHC class I expression. This function prevents the activation of NK cells against ‘self’ cells, but the lowering of MHC class I on damaged or cancer cells allows NK cells to eliminate such cells as a first line defense against aberrant cell proliferation and cancer. In humans, MHC class I molecules are recognized by a family of receptors called killer cell immunoglobin-like receptors (KIR), which can either activate or inhibit NK cell killing. Another important receptor, natural killer group 2A (NKG2A) (CD94), binds to the ubiquitously expressed HLA class I molecule HLA-E to suppress NK cell cytotoxicity. On the other hand, several activating receptors, such as natural killer group 2D (NKGD2), or DNAX accessory molecule-1 (DNAM-1), increase on NK cells upon interaction with stressed cells. NK cells are now characterized based on the expression of the specific receptors that fine-tune NK cell-mediated cytotoxicity.

The differential expression of CD56 has most often been used to identify NK cells in humans. Low (CD56dim) and high (CD56bright) CD56 expression levels define major subsets, along with an absence of CD3. CD56bright CD16− cells are considered immature NK cells that secrete IFNγ, whereas CD56dim CD16+ NK cells are responsible for cytotoxicity. Upon physical interaction with target cells, cytotoxic NK cells release perforin, granzymes (serine proteases) and proteoglycans contained in cytotoxic granules that kill the target cells.

One important consequence of the SASP is the attraction of NK cells. NK cell-mediated clearance of senescent cells is an essential aspect of tissue homeostasis and tumor growth limitation. Impairing NK cell function results in an accelerated accumulation of senescent cells in various tissues, at least in animal models. Furthermore, aging can alter NK cell cytotoxicity and cytokine production. Although NK cells from different individuals vary substantially in their expression of surface receptors, the proportion of CD56 dim NK cells increases with age, and cytokine-producing CD56bright NK cells decline after age 60 years.

DNA damage is known to induce the expression of several NK cell receptors, such as NKG2D and DNAX accessory molecule-1 (DNAM-1) ligand, on target cells. This induction has been utilized to increase the immune clearance of multiple myeloma, where induction of senescence upon treatment with genotoxic chemotherapeutic drugs like Doxorubicin enhances NK cell-mediated elimination of cancer cells due to increased expression of DNAM-1. In addition, recent studies show that senescent cells acquire mechanisms to evade clearance by NK cells. For instance, senescent fibroblasts in culture and in the skin of older humans increase expression of HLA-E, which interacts with NKG2A to inhibit NK cytotoxicity. Senescent cells can also shed MICA and MICB, which are ligands for NKG2D receptors expressed on NK cells and are primarily responsible for NK cell targeting of senescent cells. The shedding of these ligands by metalloprotease secretion as part of the SASP can prevent NK cells from binding to target cells (Fig. 1).

Interaction of other immune cell types with senescent cells

T cells are a type of lymphocyte that play a central role in adaptive immune responses. These thymus-derived cells mature by interacting with foreign antigens presented, along with MHC molecules, on antigen-presenting cells (APCs) through their T cell receptors. Depending on the microenvironment, these cells can mature into cytotoxic CD8+ cells that aid in the maturation of B cells upon subsequent interaction with pathogenic antigens presented by APCs, helper CD4+ memory cells, or natural killer T (NKT) cells. CD8+ T cells can also target senescent cells by interacting with NKG2D ligands (described above). CD4+ T cells are required for proper macrophage-dependent elimination of senescent hepatocytes (induced by oncogene expression) in vivo, suggesting that Th1 lymphocytes participate in immune surveillance of senescent cells. Further, oncogene-induced senescence in melanocytes can activate CD4+ T cell proliferation, concurrent with increased MHC II expression on senescent cells, suggesting recruitment of the adaptive immune system to prevent tumor growth. Finally, neutrophils mediate the immediate host response to bacterial and fungal infections. Along with NK cells and macrophages, neutrophils also infiltrate tissues containing senescent cells, and are susceptible to age-dependent decline in numbers and phagocytic function.

Potential therapies for the immune clearance of senescent cells

There are currently several immune cell therapies for cancer under development or approved, which could potentially be redesigned to target senescent cells. Cell-based therapies have greatly improved in recent years with the optimization of cell production, cell modifications, and storage. The following section focuses on how current cell therapies could be employed for senescent cell removal.

Therapeutic use of CAR-T cells

Chimeric antigen receptor (CAR) T cell therapy has been successful in recent years for treating diseases such as cancer. CAR-T cell therapy uses autologous cells that are genetically modified ex vivo to encode a synthetic receptor that binds a known antigen. The modified cells are then infused back into the patient to kill the target cells. A universal CAR-T cell product could eliminate many of the harvesting and manufacturing problems associated with autologous or HLA matched CAR-T cells. Advantages of CAR-T cells over other cell types include their capacity to induce durable responses and their ability to override tolerance to self-antigens. CAR-T cell targeting moieties are not restricted to antibody targets, as non-antibody structures such as aptamers and polypeptides have been used. However, a potential downside to this approach is that some antigens used to target cancer cells are also present in healthy tissues, albeit generally at much lower levels.

Evidence that there are senescent-specific surface markers is spotty, and specificity needs further validation. Nonetheless, once a good target has been identified, it can be used to create a CAR-T cell. Alternative CAR-T strategies are being developed to improve specificity or effectiveness that could be helpful in the context of senescent cells. One such alteration is the use of several antigens for improved recognition, allowing more specific recognition of senescent cells. The therapeutic potential of CAR-T cells in targeting senescent cells stems from their success in the treatment of solid tumors, as CAR-T cells are observed to reach deep into the parenchyma of many different organs in which senescent cells reside.

Therapeutic use of natural killer cells

As senescent cells are naturally targeted for elimination by NK cells, it could be beneficial to use NK cells to eliminate persistent pro-inflammatory senescent cells, particularly as they accumulate during aging. The broad cytotoxicity and rapid killing ability make NK cells ideal for use in cancer immunotherapy. Indeed, long before the era of CAR-T cells, researchers used NK cells to fight cancers. NK cells have been an attractive choice for allogeneic immunotherapy for various cancers such as acute myeloid leukemia, and can be easily isolated and enriched from a variety of sources like peripheral blood, bone marrow or cord blood. NK cells isolated from healthy young donors are not only fully functional, but can also eliminate cancer cells by robust graft-versus tumor response as they do not express inhibitory receptors specific to host cells. Even though, technical, logistical and financial challenges are still limiting factors for applications of circulating NK cells as promising cancer therapies, over the past decade, several studies demonstrated the safety and efficacy of allogeneic NK cells against various hematological malignancies and, to a lesser extent, solid tumors. Further, induced pluripotent stem cells have been genetically modified with an NK-CAR construct and differentiated into NK cells. These cells were tested in a mouse tumor model and were effective at eliciting a lower cytokine level in recipients, indicating that these cells might be safer, given that repeated administration is needed. The same technology could be used to target senescent cells by NK cells.

An additional benefit of NK-CAR cells over CAR-T cells is that the former retains their ability to recognize target cells through their native receptors, making it less likely for tumor cells to escape by downregulating the CAR target antigen. NK-CAR cells do not undergo clonal expansion or quick immune rejection. NK cells do not require strict HLA matching and lack the potential to cause graft-versus-host disease, an important risk imposed by CAR-T cell therapy. NK-CAR cells could therefore be an off-the-shelf allogeneic therapeutic for the effective elimination of pro-inflammatory senescent cells. On the other hand, senescent cells can escape NK-mediated killing by overexpressing MMP3 (which cleaves activating MICA ligands from the senescent cell surface) or HLA-E (an inhibitory ligand that blocks NK cell killing). Unfortunately, MMP-3 inhibitors have serious side effects and thus are not generally useful.

Therapeutic use of macrophages

As discussed above, macrophages can eliminate senescent cells. Transplanted macrophages can migrate into tissues and become tissue-resident with much longer half-lives and self-renewal abilities. Targets for macrophage cell therapies are more numerous than other cell types and potentially include cancers, myocardial infarcts, osteoporosis and Alzheimer’s disease. Indeed, because macrophages are phenotypically plastic, and cancer cells often express a “don’t eat me” signal, these therapies have not been very successful in treating cancer. Whether this limitation poses a difficulty in using macrophages against senescent cells is not clear. Further, NFκB-dependent pro-inflammatory signaling appears to upregulate CD47, at least in some cancers, facilitating their escape from immune surveillance. Senescent cells generally upregulate NFκB activity, which can activate CD47 transcription. As a cell surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPα), CD47 serves as an inhibitory receptor on macrophages. It is possible that some senescent evade macrophage-mediated killing by increasing CD47 signaling, in some cases by secreting its ligand, thrombospondin. Notably, some macrophages have been engineered to lack the SIRPα co-receptor to overcome this evasion. Moreover, allogeneic macrophages from young donors or induced pluripotent stem cells (iPS) would probably be more effective at removing senescent cells, as they have a higher phagocytosis capacity.

Conclusions

A better understanding of the interplay between immune cells and senescent cells would illuminate changes that happen during aging, and also speed the development of novel therapeutic interventions for eliminating deleterious senescent cells. Different approaches could be formulated to remove senescent cells using the natural ability of immune cells. What is needed now is a more thorough understanding of the heterogeneity of senescent cells and of the specific targets for immune cells. In addition, it will be important to determine how tissue resident macrophages interact with senescent cells, and whether the propagation of paracrine senescence increases the senescent cell burden. Finally, it will be critical to understand the mechanisms by which senescent cells escape immune clearance.

References 121

  1. 1.

    Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001;11:S27-S31.

    Not in our library10.1016/s0962-8924(01)02151-1

  2. 2.

    Campisi, J., and d’Adda di Fagagna, F. (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8, 729–740.

    Not in our library10.1038/nrm2233

  3. 3.

    Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482-496.

    Not in our library10.1038/nrm3823

  4. 4.

    Victorelli S, Passos JF. Telomeres and cell senescence - size matters not. EBioMedicine. 2017;21:14-20.

    Not in our library10.1016/j.ebiom.2017.03.027

  5. 5.

    d’Adda di Fagagna, F. (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8, 512–522.

    Not in our library10.1038/nrc2440

  6. 6.
    Small molecule compounds that induce cellular senescence · 2016
    No notice
  7. 7.

    Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397-408.

    Not in our library10.1038/nrc3960

  8. 8.

    Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, Shirakawa K, Lim HW, Davis SS, Ramanathan A, Gerencser AA, Verdin E, Campisi J. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016;23:303-314.

    Not in our library10.1016/j.cmet.2015.11.011

  9. 9.

    Duan J, Duan J, Zhang Z, Tong T. Irreversible cellular senescence induced by prolonged exposure to H2O2 involves DNA-damage-and-repair genes and telomere shortening. Int J Biochem Cell Biol. 2005;37:1407-1420.

    Not in our library10.1016/j.biocel.2005.01.010

  10. 10.

    Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr Biol. 2017;27:2652-2660.

    Not in our library10.1016/j.cub.2017.07.033

  11. 11.
    Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor · 2008
    No notice
  12. 12.
    A Human-Like Senescence-Associated Secretory Phenotype Is Conserved in Mouse Cells Dependent on Physiological Oxygen · 2010
    No notice
  13. 13.

    Neves J, Demaria M, Campisi J, Jasper H. Of flies, mice, and men: evolutionarily conserved tissue damage responses and aging. Dev Cell. 2015;32:9-18.

    Not in our library10.1016/j.devcel.2014.11.028

  14. 14.
    A proteomic atlas of senescence-associated secretomes for aging biomarker development · 2020
    No notice
  15. 15.

    Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev. 2011;21:107-112.

    Not in our library10.1016/j.gde.2010.10.005

  16. 16.

    Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol. 2014;69:54-59.

    Not in our library10.1093/gerona/glu057

  17. 17.

    van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509:439-446.

    Not in our library10.1038/nature13193

  18. 18.

    Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.

    Not in our library10.1146/annurev-pathol-121808-102144

  19. 19.

    Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.

    Not in our library10.1146/annurev-physiol-030212-183653

  20. 20.

    Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vasserot AP, Chung JW, Kim DH, Poon Y, David N, Baker DJ, van Deursen JM, Campisi J, Elisseeff JH. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23:775-781.

    Not in our library10.1038/nm.4324

  21. 21.

    Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM, LeBrasseur NK, Drake MT, Pignolo RJ, Pirtskhalava T, Tchkonia T, Oursler MJ, Kirkland JL, Khosla S. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23:1072-1079.

    Not in our library10.1038/nm.4385

  22. 22.

    Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016;354:472-477.

    Not in our library10.1126/science.aaf6659

  23. 23.

    Chinta SJ, Woods G, Demaria M, Rane A, Zou Y, McQuade A, Rajagopalan S, Limbad C, Madden DT, Campisi J, Andersen JK. Cellular senescence is induced by the environmental neurotoxin Paraquat and contributes to neuropathology linked to Parkinson's disease. Cell Rep. 2018;22:930-940.

    Not in our library10.1016/j.celrep.2017.12.092

  24. 24.

    Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578-582.

    Not in our library10.1038/s41586-018-0543-y

  25. 25.
    Tau protein aggregation is associated with cellular senescence in the brain · 2018
    No notice
  26. 26.

    Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness R, Jeganathan KB, Casaclang Versoza GC, Pezeshki A, Khazaie K, Miller JD, van Deursen JM. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530:184-189.

    Not in our library10.1038/nature16932

  27. 27.

    Baar MP, Brandt RM, Putavet DA, Klein JD, Derks KW, Bourgeois BR, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RW, Madl T, Hoeijmakers JH, Campisi J, de Keizer PL. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169:132-147.

    Not in our library10.1016/j.cell.2017.02.031

  28. 28.

    Demaria M, O’Leary M, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM, Alston S, Academia E, Klimarx S, Valdovinos A, Wang B, de Bruin A, Kennedy BK, Melov S, Zhou D, Sharpless NE, Muss H, Campisi J. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Disc. 2017;7:165-176.

    Not in our library10.1158/2159-8290.cd-16-0241

  29. 29.
    Cellular senescence mediates fibrotic pulmonary disease · 2017
    No notice
  30. 30.

    Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG, Onken JL, Johnson KO, Verzosa GC, Langhi LGP, Weigl M, Giorgadze N, LeBrasseur NK, Miller JD, Jurk D, Singh RJ, Allison DB, Ejima K, Hubbard GB, Ikeno Y, Cubro H, Garovic VD, Hou X, Weroha SJ, Robbins PD, Niedernhofer LJ, Khosla S, Tchkonia T, Kirkland JL. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24:1246-1256.

    Not in our library10.1038/s41591-018-0092-9

  31. 31.

    Mosteiro L, Pantoja C, Alcazar N, Marion RM, Chondronasiou D, Rovira M, Fernandez-Marcos PJ, Munoz-Martin M, Blanco-Aparicio C, Pastor J, Gomez-Lopez G, De Martino A, Blasco MA, Abad M, Serrano M. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science. 2016;354:aaf4445.

    Not in our library10.1126/science.aaf4445

  32. 32.

    Ocampo A, Reddy P, Belmonte JCI. Anti-aging strategies based on cellular reprogramming. Trends Mol Med. 2016;22:725-738.

    Not in our library10.1016/j.molmed.2016.06.005

  33. 33.

    Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134:657-667.

    Not in our library10.1016/j.cell.2008.06.049

  34. 34.

    Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol. 2010;12:676-685.

    Not in our library10.1038/ncb2070

  35. 35.
    Senescent Cardiac Fibroblast Is Critical for Cardiac Fibrosis after Myocardial Infarction · 2013
    No notice
  36. 36.

    Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, Laberge RM, Vijg J, Van Steeg H, Dolle ME, Hoeijmakers JH, de Bruin A, Hara E, Campisi J. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31:722-733.

    Not in our library10.1016/j.devcel.2014.11.012

  37. 37.

    Meyer K, Hodwin B, Ramanujam D, Engelhardt S, Sarikas A. Essential role for premature senescence of Myofibroblasts in myocardial fibrosis. J Am Coll Cardiol. 2016;67:2018-2028.

    Not in our library10.1016/j.jacc.2016.02.047

  38. 38.

    Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, Yosef R, Pilpel N, Krizhanovsky V, Sharpe J, Keyes WM. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013;155:1119-1130.

    Not in our library10.1016/j.cell.2013.10.041

  39. 39.

    Munoz-Espin D, Canamero M, Maraver A, Gomez-Lopez G, Contreras J, Murillo-Cuesta S, Rodriguez-Baeza A, Varela-Nieto I, Ruberte J, Collado M, Serrano M. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155:1104-1118.

    Not in our library10.1016/j.cell.2013.10.019

  40. 40.

    Feng T, Meng J, Kou S, Jiang Z, Huang X, Lu Z, Zhao H, Lau LF, Zhou B, Zhang H. CCN1-induced cellular senescence promotes heart regeneration. Circulation. 2019;139:2495-2498.

    Not in our library10.1161/circulationaha.119.039530

  41. 41.

    Sarig R, Rimmer R, Bassat E, Zhang L, Umansky KB, Lendengolts D, Perlmoter G, Yaniv K, Tzahor E. Transient p53-mediated regenerative senescence in the injured heart. Circulation. 2019;139:2491-2494.

    Not in our library10.1161/circulationaha.119.040125

  42. 42.

    Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11:398-411.

    Not in our library

  43. 43.

    Burton DGA, Stolzing A. Cellular senescence: Immunosurveillance and future immunotherapy. Ageing Res Rev. 2018;43:17-25.

    Not in our library10.1016/j.arr.2018.02.001

  44. 44.

    Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-660.

    Not in our library10.1038/nature05529

  45. 45.

    Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013;210:2057-2069.

    Not in our library10.1084/jem.20130783

  46. 46.

    Tasdemir N, Banito A, Roe J-S, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang C-H, Aksoy O, Bolden JE, Chen C-C, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW. BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discov. 2016;6:612-629.

    Not in our library10.1158/2159-8290.cd-16-0217

  47. 47.

    Chong M, Yin T, Chen R, Xiang H, Yuan L, Ding Y, Pan CC, Tang Z, Alexander PB, Li QJ, Wang XF. CD36 initiates the secretory phenotype during the establishment of cellular senescence. EMBO Rep. 2018;19:e45274.

    Not in our library10.15252/embr.201745274

  48. 48.

    MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-350.

    Not in our library10.1146/annurev.immunol.15.1.323

  49. 49.

    Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-6173.

    Not in our library10.4049/jimmunol.1701141

  50. 50.

    Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. (2017) Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol. 2000;164:6166-6173.

    Not in our library10.4049/jimmunol.1701141

  51. 51.

    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801.

    Not in our library10.1016/j.cell.2006.02.015

  52. 52.
    Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? · 2018
    No notice
  53. 53.

    Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.

    Not in our library10.1146/annurev.immunol.15.1.749

  54. 54.

    Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci U S A. 1989;86:3803-3807.

    Not in our library10.1073/pnas.86.10.3803

  55. 55.

    Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533-6544.

    Not in our library10.4049/jimmunol.167.11.6533

  56. 56.

    Mevorach D, Trahtemberg U, Krispin A, Attalah M, Zazoun J, Tabib A, Grau A, Verbovetski-Reiner I. What do we mean when we write “senescence,” “apoptosis,” “necrosis,” or “clearance of dying cells”? Ann N Y Acad Sci. 2010;1209:1-9.

    Not in our library10.1111/j.1749-6632.2010.05774.x

  57. 57.

    Egashira M, Hirota Y, Shimizu-Hirota R, Saito-Fujita T, Haraguchi H, Matsumoto L, Matsuo M, Hiraoka T, Tanaka T, Akaeda S, Takehisa C, Saito-Kanatani M, Maeda K-I, Fujii T, Osuga Y. F4/80+ macrophages contribute to clearance of senescent cells in the mouse postpartum uterus. Endocrinology. 2017;158:2344-2353.

    Not in our library10.1210/en.2016-1886

  58. 58.

    Irvine KM, Skoien R, Bokil NJ, Melino M, Thomas GP, Loo D, Gabrielli B, Hill MM, Sweet MJ, Clouston AD, Powell EE. Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. World J Gastroenterol. 2014;20:17851-17862.

    Not in our library10.3748/wjg.v20.i47.17851

  59. 59.

    Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, Lowe SW. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153:449-460.

    Not in our library10.1016/j.cell.2013.03.020

  60. 60.

    Dimitrijevi, M., Stanojevi, S., Blagojevi, V., uruvija, I., Vujnovi, I., Petrovi, R., Arsenovi?-Ranin, N., Vuji, V., and Leposavi, G. (2016) Aging affects the responsiveness of rat peritoneal macrophages to GM-CSF and IL-4. Biogerontology 17, 359–371.

    Not in our library10.1007/s10522-015-9620-x

  61. 61.

    Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K, Bouchaert E, Vanhoutte J, Fleury S, Remy P, Tailleux A, Chinetti-Gbaguidi G, Dombrowicz D, Staels B, Paumelle R. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood. 2011;118:2556-2566.

    Not in our library10.1182/blood-2010-10-313106

  62. 62.

    Mazzoni M, Mauro G, Erreni M, Romeo P, Minna E, Vizioli MG, Belgiovine C, Rizzetti MG, Pagliardini S, Avigni R, Anania MC, Allavena P, Borrello MG, Greco A. Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism. J Exp Clin Cancer Res. 2019;38:208.

    Not in our library10.1186/s13046-019-1198-8

  63. 63.

    Wiley CD, Brumwell AN, Davis SS, Jackson JR, Valdovinos A, Calhoun C, Alimirah F, Castellanos CA, Ruan R, Wei Y, Chapman HA, Ramanathan A, Campisi J, Jourdan Le Saux C. Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis. JCI Insight. 2019;4:e130056.

    Not in our library10.1172/jci.insight.130056

  64. 64.

    Franceschi C, Bonafe M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31:457-461.

    Not in our library10.1042/bst0310457

  65. 65.

    Liu J-Y, Souroullas GP, Diekman BO, Krishnamurthy J, Hall BM, Sorrentino JA, Parker JS, Sessions GA, Gudkov AV, Sharpless NE. Cells exhibiting strong p16 INK4a promoter activation in vivo display features of senescence. Proc Natl Acad Sci U S A. 2019;116:2603-2611.

    Not in our library10.1073/pnas.1818313116

  66. 66.
    Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells · 2016
    No notice
  67. 67.
    The bystander effect contributes to the accumulation of senescent cells in vivo · 2018
    No notice
  68. 68.

    Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15:978-990.

    Not in our library10.1038/ncb2784

  69. 69.
    p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli · 2017
    No notice
  70. 70.

    Covarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Wiley CD, Iyer SS, Basisty N, Wu Q, Kwok R, Heckenbach I, Shin K-O, Lee Y-M, Ben-Sahra I, Ott M, Schilling B, Ishihara K, Quake SR, Newman J, Brenner C, Campisi J, Verdin E. Aging-related inflammation driven by cellular senescence enhances NAD consumption via activation of CD38+ pro-inflammatory macrophages. bioRxiv. 2019:609438. 10.1101/609438.

    Not in our library

  71. 71.

    Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17:34-40.

    Not in our library10.1038/ni.3324

  72. 72.

    Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541-566.

    Not in our library10.1146/annurev-physiol-022516-034339

  73. 73.

    Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol. 2005;61:10-17.

    Not in our library10.1111/j.0300-9475.2005.01524.x

  74. 74.

    Lingnau M, Hoflich C, Volk HD, Sabat R, Docke WD. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol. 2007;68:730-738.

    Not in our library10.1016/j.humimm.2007.06.004

  75. 75.

    Rosenberg EB, Herberman RB, Levine PH, Halterman RH, McCoy JL, Wunderlich JR. Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer. 1972;9:648-658.

    Not in our library10.1002/ijc.2910090323

  76. 76.

    Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648.

    Not in our library10.1146/annurev.immunol.14.1.619

  77. 77.

    Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med. 2005;201:1025-1029.

    Not in our library10.1084/jem.20050499

  78. 78.

    Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132:315-325.

    Not in our library10.1111/j.1365-2567.2010.03398.x

  79. 79.

    Thomas LM. Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors. Immunotargets Ther. 2015;4:45-53.

    Not in our library10.2147/itt.s61498

  80. 80.

    Strong RK. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. Mol Immunol. 2002;38:1029-1037.

    Not in our library10.1016/s0161-5890(02)00032-9

  81. 81.

    Shibuya A, Lanier LL, Phillips JH. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol. 1998;161:1671-1676.

    Not in our library

  82. 82.

    Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 2014;21:5-14.

    Not in our library10.1038/cdd.2013.26

  83. 83.

    Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.

    Not in our library10.1146/annurev.immunol.19.1.197

  84. 84.

    Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6:940-952.

    Not in our library10.1038/nri1983

  85. 85.

    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218.

    Not in our library10.1172/jci24282

  86. 86.
    Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium · 2017
    No notice
  87. 87.

    Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene. 2013;32:1971-1977.

    Not in our library10.1038/onc.2012.206

  88. 88.
    Impaired immune surveillance accelerates accumulation of senescent cells and aging · 2018
    No notice
  89. 89.
    The impact of ageing on natural killer cell function and potential consequences for health in older adults · 2013
    No notice
  90. 90.

    Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, Mace EM, Orange JS. Practical NK cell phenotyping and variability in healthy adults. Immunol Res. 2015;62:341-356.

    Not in our library10.1007/s12026-015-8664-y

  91. 91.

    Gounder SS, Abdullah BJJ, Radzuanb NEIBM, Zain FDBM, Sait NBM, Chua C, Subramani B. Effect of aging on NK cell population and their proliferation at ex vivo culture condition. Anal Cell Pathol (Amst). 2018;2018:7871814.

    Not in our library10.1155/2018/7871814

  92. 92.
    Ageing is associated with a decline in peripheral blood CD56bright NK cells · 2006
    No notice
  93. 93.
    The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells · 2014
    No notice
  94. 94.

    Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113:3503-3511.

    Not in our library10.1182/blood-2008-08-173914

  95. 95.

    Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, Bernardini G, Santoni A. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells. Oncoimmunology. 2016;5:e1218105.

    Not in our library10.1080/2162402x.2016.1218105

  96. 96.

    Antonangeli F, Zingoni A, Soriani A, Santoni A. Senescent cells: living or dying is a matter of NK cells. J Leukoc Biol. 2019;105:1275-1283.

    Not in our library10.1002/jlb.mr0718-299r

  97. 97.
    Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition · 2019
    No notice
  98. 98.

    Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer, L. J., Campisi, J., and Coppe, J. P. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019;5:e124716.

    Not in our library10.1172/jci.insight.124716

  99. 99.

    Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J Immunol. 2015;195:736–48.

    Not in our library10.4049/jimmunol.1402643

  100. 100.

    Santamaria J, Darrigues J, van Meerwijk JPM, Romagnoli P. Antigen-presenting cells and T-lymphocytes homing to the thymus shape T cell development. Immunol Lett. 2018;204:9-15.

    Not in our library10.1016/j.imlet.2018.10.003

  101. 101.

    Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547-551.

    Not in our library10.1038/nature10599

  102. 102.

    van Tuyn J, Jaber-Hijazi F, MacKenzie D, Cole JJ, Mann E, Pawlikowski JS, Rai TS, Nelson DM, McBryan T, Ivanov A, Blyth K, Wu H, Milling S, Adams PD. Oncogene-expressing senescent melanocytes up-regulate MHC class II, a candidate melanoma suppressor function. J Invest Dermatol. 2017;137:2197-2207.

    Not in our library10.1016/j.jid.2017.05.030

  103. 103.

    Butcher S, Chahel H, Lord JM. Review article: ageing and the neutrophil: no appetite for killing? Immunology. 2000;100:411-416.

    Not in our library10.1046/j.1365-2567.2000.00079.x

  104. 104.

    Moutsatsou P, Ochs J, Schmitt RH, Hewitt CJ, Hanga MP. Automation in cell and gene therapy manufacturing: from past to future. Biotechnol Lett. 2019;41:1245-1253.

    Not in our library10.1007/s10529-019-02732-z

  105. 105.
    Genetically modified T cells in cancer therapy: opportunities and challenges · 2015
    Not checked
  106. 106.

    Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018;16:375-386.

    Not in our library

  107. 107.

    Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019;141:41-46.

    Not in our library10.1016/j.addr.2019.04.006

  108. 108.
    CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment · 2019
    No notice
  109. 109.

    Di Vito C, Mikulak J, Zaghi E, Pesce S, Marcenaro E, Mavilio D. NK cells to cure cancer. Semin Immunol. 2019;41:101272.

    Not in our library10.1016/j.smim.2019.03.004

  110. 110.

    Fang F, Xiao W, Tian Z. Challenges of NK cell-based immunotherapy in the new era. Front Med. 2018;12:440-450.

    Not in our library10.1007/s11684-018-0653-9

  111. 111.
    Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy · 2019
    No notice
  112. 112.

    Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(181–192):e185.

    Not in our library10.1016/j.stem.2018.06.002

  113. 113.

    Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for Cancer immunotherapy. Mol Ther. 2017;25:1769-1781.

    Not in our library10.1016/j.ymthe.2017.06.012

  114. 114.

    Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, Lucas D, Greter M, Mortha A, Boyer SW, Forsberg EC, Tanaka M, van Rooijen N, Garcia-Sastre A, Stanley ER, Ginhoux F, Frenette PS, Merad M. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38:792-804.

    Not in our library10.1016/j.immuni.2013.04.004

  115. 115.

    Lee S, Kivimae S, Dolor A, Szoka FC. Macrophage-based cell therapies: the long and winding road. J Control Release. 2016;240:527-540.

    Not in our library10.1016/j.jconrel.2016.07.018

  116. 116.
    A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer · 2017
    No notice
  117. 117.

    Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62:534-545.

    Not in our library10.1002/hep.27859

  118. 118.

    Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610-2620.

    Not in our library10.1172/jci81603

  119. 119.

    Ray M, Lee YW, Hardie J, Mout R, Yesilbag Tonga G, Farkas ME, Rotello VM. CRISPRed macrophages for cell-based Cancer immunotherapy. Bioconjug Chem. 2018;29:445-450.

    Not in our library10.1021/acs.bioconjchem.7b00768

  120. 120.

    Ackermann M, Kuhn A, Kunkiel J, Merkert S, Martin U, Moritz T, Lachmann N. Ex vivo generation of genetically modified macrophages from human induced pluripotent stem cells. Transfus Med Hemother. 2017;44:135-142.

    Not in our library10.1159/000477129

  121. 121.
    Macrophages in age-related chronic inflammatory diseases · 2016
    No notice

Cited by papers we hold 12

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.